InfuSystem Holdings, Inc Q3 FY2026 earnings call

• Strategic Growth & Product Performance: The company highlighted strong execution of its profitable growth strategy, with accelerated pro forma growth reaching 10.2% in Q3, up from 1.7% in Q1. The Wound Care segment, particularly lymphedema treatments, is scaling rapidly and validating the strategy of leveraging existing infrastructure for complementary therapies.
• Profitability Expansion: Adjusted EBITDA margin expanded significantly to 24.9% from 22.8% in the prior year period. This improvement was driven by the favorable economics of the GE Healthcare contract restructuring, operational efficiency initiatives, and declining ERP-related implementation expenses.
• Operational Improvements & ERP Transition: The firm is transitioning to new ERP and revenue cycle management systems. While this caused temporary working capital pressure due to invoice formatting issues, corrective actions were implemented, and collection trends have stabilized. Management expects these technology investments to lower the breakeven point for processing claims, enabling more efficient scaling.
• Financial Discipline & Cash Flow: Operating cash flow for the first nine months increased 5% to $18.1 million. Net debt was reduced by $8.9 million to approximately $10.6 million (0.32x trailing adjusted EBITDA), demonstrating strengthened balance sheet flexibility despite minor billing delays.

Total revenue increased 3% year-over-year to $37.6 million, with pro forma revenue growth of 10.2% after adjusting for the GE Healthcare contract restructuring. Within Patient Services, Oncology revenue grew 7.2%, driven by increased treatment volume, improved reimbursement rates, and better collections. Wound Care delivered exceptional growth of 112%, largely fueled by compression therapy products (contributing approximately $1.6 million in growth) and negative pressure wound therapy. In Device Solutions, Biomedical Services revenue grew 19.8% on a pro forma basis, supported by strong device repair volumes and field projects; however, this was partially offset by lower equipment sales and softer disposable product revenue.

• Full-Year Revenue: Reaffirmed pro forma revenue growth guidance of 6% to 8% for fiscal year 2026, excluding the impact of the GE Healthcare contract restructuring.
• Margin Outlook: Maintained expectation for adjusted EBITDA margins to remain in the low to mid-20% range for the full year.
• Investment Plan: Noted that modest additional investments in workflow automation and software-enabled process improvements are expected to begin in the fourth quarter to support long-term efficiency and scale.

• ERP Implementation Challenges: The transition to new enterprise resource planning systems resulted in temporary working capital pressure, specifically regarding delayed invoicing and customer-required invoice format revisions, though these issues have been identified and corrected.
• Margin Pressure from New Business: Incoming new business opportunities may carry lower gross margins than existing operations, requiring continuous cost reduction efforts to maintain target EBITDA margins.
• Inflationary Costs: Ongoing inflationary pressures on costs remain a factor that management must offset through procurement initiatives and productivity improvements.

Q: Tollef Kohrman asked about the sustainability of Wound Care’s 112% growth and return expectations for recent tech investments. Carrie Lachance confirmed that referrals remain strong and volume is expected to hold steady in Q4, with new systems enhancing future growth. Barry Steele added that investments aim to lower the breakeven point for claim processing via machine learning, allowing the company to efficiently handle smaller claims and scale faster.

Q: James Sidoti inquired about the status of the ERP-related delay in the earnings release and the nature of Oncology’s growth. Barry Steele clarified that the audit issue was fully resolved with no financial changes. Carrie Lachance explained that Oncology growth is driven by new customers, rate increases, and workflow automation within client ERPs. She noted that migrating Oncology to the new revenue cycle system is delayed until year-end or early next year to ensure stability.

Q: Benjamin Haynor sought clarification on the wide implied range of the 'low to mid-20%' EBITDA margin guidance for Q4. Barry Steele refined the definition, stating it represents a tighter band of 22% to 25%, not 20% to 25%. Carrie Lachance indicated that by mid-2027, the company expects significant volume growth from new partnerships as the technology foundation matures.